TTR and primary hyperoxaluria type 1: Despite the FDA approval of five siRNA drugs for the treatment of hereditary transthyretin-induced amyloidosis with polyneuropathy, hypercholesterolemia, primary hyperoxaluria type 1, and hepatic porphyria, their usefulness for other diseases and the development of new siRNA-based therapeutics are intricate and challenging [103].